🇺🇸 FDA
Pipeline program

SHR-1139 Injection

PG-IIT-SHR1139

Phase 2 small_molecule active

Quick answer

SHR-1139 Injection for Pyoderma Gangrenosum is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Pyoderma Gangrenosum
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials